{"DataElement":{"publicId":"2902396","version":"1","preferredName":"CML Disease Phase Category","preferredDefinition":"Categorization/classification of patients with chronic myelogenous leukemia or CML, the most common chronic myeloproliferative disorder finding by well-defined periods of disease increased activity or indolence.","longName":"CML_DZ_PHASE_CAT","context":"NCI Standards","contextVersion":"1","DataElementConcept":{"publicId":"2902393","version":"1","preferredName":"CML Disease Phase","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003_Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._Phase; any distinct time period in a sequence of events","longName":"CML_DZ_PHASE","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2500393","version":"1","preferredName":"CML","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003","longName":"C3174","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"1995DB3E-65B1-6546-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-07-27","endDate":null,"createdBy":"PWEST","dateCreated":"2006-07-27","modifiedBy":"ONEDATA","dateModified":"2006-07-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2902391","version":"1","preferredName":"Disease or Disorder Phase","preferredDefinition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.:Phase; any distinct time period in a sequence of events","longName":"C2991:C25257","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Phase","conceptCode":"C25257","definition":"A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C9E82E9-209D-FAAA-E040-BB89AD43173F","latestVersionIndicator":"Yes","beginDate":"2009-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-06-18","modifiedBy":"ONEDATA","dateModified":"2009-06-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C9E82E9-20AE-FAAA-E040-BB89AD43173F","latestVersionIndicator":"Yes","beginDate":"2009-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-06-18","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2902394","version":"1","preferredName":"CML Phase Category","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003_A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle._Category; used informally to mean a class of things.","longName":"CML_PHASE_CAT","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"18","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Chronic phase","valueDescription":"Chronic Phase Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"2675140","version":"1","preferredName":"Chronic Phase Chronic Myelogenous Leukemia","longName":"2675140","preferredDefinition":"A phase of chronic myelogenous leukemia in which the peripheral blood smear shows leukocytosis due mainly to neutrophils in different stages of maturation.  Blasts usually account for less than 2% of the white blood cells counts.  The platelet count is normal or increased.  Thrombocytopenia is very uncommon during the chronic phase.  Most patients have mild anemia.  The bone marrow biopsy is hypercellular due to increased numbers of neutrophils and their precursors.  Blasts usually account for fewer than 5% of the marrow cells, and more than 10% indicates transformation to the accelerated phase.  Megakaryocytes are smaller than normal and have hypolobated nuclei.  The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.  Most patients with chronic myelogenous leukemia are diagnosed in the chronic phase, which usually has an insidious onset and may last from several months to several years. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3175","definition":"A phase of chronic myeloid leukemia in which the peripheral blood smear shows leukocytosis due mainly to neutrophils in different stages of maturation.  Blasts usually account for less than 2% of the white blood cells counts.  The platelet count is normal or increased.  Thrombocytopenia is very uncommon during the chronic phase.  Most patients have mild anemia.  The bone marrow biopsy is hypercellular due to increased numbers of neutrophils and their precursors.  Blasts usually account for fewer than 5% of the marrow cells, and more than 10% indicates transformation to the accelerated phase.  Megakaryocytes are smaller than normal and have hypolobated nuclei.  The spleen is enlarged due to infiltration of the cords of the red pulp by granulocytes.  Most patients with chronic myelogenous leukemia are diagnosed in the chronic phase, which usually has an insidious onset and may last from several months to several years. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38DBE882-E410-674F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C9F2890-0C0B-3C66-E040-BB89AD435C35","beginDate":"2009-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-06-18","modifiedBy":"ONEDATA","dateModified":"2009-06-18","deletedIndicator":"No"},{"value":"Accelerated phase","valueDescription":"Accelerated Phase Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"2675144","version":"1","preferredName":"Accelerated Phase Chronic Myelogenous Leukemia","longName":"2675144v1.00","preferredDefinition":"A phase of chronic myeloid leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3173","definition":"A phase of chronic myeloid leukemia characterized by one or more of the following: 1) Myeloblasts accounting for 10-19% of the peripheral blood white cells or of the nucleated cells in the bone marrow, 2) peripheral blood basophils at least 20%, 3) persistent thrombocytopenia that is unrelated to therapy, 4) persistent thrombocytosis despite adequate therapy, 5) increasing white blood cell count and increasing spleen size unresponsive to therapy, and/or evidence of clonal evolution. (WHO, 2001)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38DBE882-E460-674F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-29","modifiedBy":"KUMMEROA","dateModified":"2023-08-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C9F2890-0C20-3C66-E040-BB89AD435C35","beginDate":"2009-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-06-18","modifiedBy":"ONEDATA","dateModified":"2009-06-18","deletedIndicator":"No"},{"value":"Blastic phase","valueDescription":"Blast Phase Chronic Myelogenous Leukemia","ValueMeaning":{"publicId":"2675142","version":"1","preferredName":"Blast Phase Chronic Myelogenous Leukemia","longName":"2675142","preferredDefinition":"An advanced phase of chronic myelogenous leukemia.  It is characterized a. by the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or b. an extramedullary proliferation of blasts, and/or c. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C9110","definition":"An advanced phase of chronic myeloid leukemia.  It is characterized by: 1.  the presence of blasts in the peripheral blood or bone marrow that are at least 20% of the peripheral blood white cells or of the nucleated cells in the bone marrow respectively, or 2. an extramedullary proliferation of blasts, and/or 3. when there are large aggregates and clusters of blasts in the bone marrow biopsy specimen (adapted from WHO, 2001).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"38DBE882-E438-674F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-08-29","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-08-29","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"6C9F2890-0C35-3C66-E040-BB89AD435C35","beginDate":"2009-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-06-18","modifiedBy":"ONEDATA","dateModified":"2009-06-18","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2677055","version":"1","preferredName":"CML Phase Category","preferredDefinition":"The most common chronic myeloproliferative disorder characterized by neutrophilic leukocytosis.  It is associated with the Philadelphia (Ph) chromosome and/or the BCR/ABL fusion gene.  Most patients are middle-aged or elderly.  Common findings at presentation include fatigue, weight loss, anemia, night sweats, and splenomegaly.  The disease is bi- or triphasic: an initial indolent chronic phase is followed by accelerated or blast phase.  Allogeneic bone marrow transplantation is currently the only curative therapy (adapted from WHO 2001).  -- 2003:Phase; any distinct time period in a sequence of events:Category; used informally to mean a class of things.","longName":"C3174:C25257:C25372","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Chronic Myeloid Leukemia, BCR-ABL1 Positive","conceptCode":"C3174","definition":"A chronic myeloproliferative neoplasm characterized by the expression of the BCR-ABL1 fusion gene. It presents with neutrophilic leukocytosis. It can appear at any age, but it mostly affects middle aged and older individuals. Patients usually present with fatigue, weight loss, anemia, night sweats, and splenomegaly. If untreated, it follows a biphasic or triphasic natural course; an initial indolent chronic phase which is followed by an accelerated phase, a blast phase, or both. Allogeneic stem cell transplantation and tyrosine kinase inhibitors delay disease progression and prolong overall survival.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Phase","conceptCode":"C25257","definition":"A distinguishable part, a stage in a series of events or in a process of development, e.g. any of the varying aspects or stages in course of a disease; a fraction of a cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Category","conceptCode":"C25372","definition":"A grouping of items based on some commonality or by user defined characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3962C2E7-37D5-03A4-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-09-05","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-09-05","modifiedBy":"ONEDATA","dateModified":"2007-09-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"6C9F2890-0BF8-3C66-E040-BB89AD435C35","latestVersionIndicator":"Yes","beginDate":"2009-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-06-18","modifiedBy":"KUMMEROA","dateModified":"2023-08-22","changeDescription":null,"administrativeNotes":"2023.8.22 Updated PV def for 'No Value Exists'. ak","unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"10000201","version":"1","longName":"Leukemia","context":"NCIP"},{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"}]},{"publicId":"3461150","version":"1","longName":"Staging","context":"NCIP","ClassificationSchemeItems":[{"publicId":"3461152","version":"1","longName":"Hematologic Staging","context":"NCIP"}]},{"publicId":"5635300","version":"1","longName":"Case Report Form (CRF) Modules","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000689","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCI Standards"}]}],"AlternateNames":[{"name":"LCC","type":"USED_BY","context":"LCC"},{"name":"AECC","type":"USED_BY","context":"AECC"},{"name":"CITN","type":"USED_BY","context":"CITN"},{"name":"PBTC","type":"USED_BY","context":"PBTC"},{"name":"OHSU Knight","type":"USED_BY","context":"OHSU Knight"}],"ReferenceDocuments":[{"name":"CML Phase","type":"Preferred Question Text","description":"CML Phase","url":null,"context":"NCI Standards"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Preferred Standard","id":"6C9F2890-0C40-3C66-E040-BB89AD435C35","latestVersionIndicator":"Yes","beginDate":"2009-06-18","endDate":null,"createdBy":"REEVESD","dateCreated":"2009-06-18","modifiedBy":"HARTLEYG","dateModified":"2021-06-17","changeDescription":"Curated as part of NCI CRF Standards staging module","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}